newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe aut